Group 1 - A class action has been filed on behalf of investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025 [1] - Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1] - The complaint alleges that Altimmune misled investors regarding the viability of its IMPACT Phase 2b MASH trial, which failed to achieve statistical significance due to a higher-than-expected placebo response [2] Group 2 - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price fell from $7.71 to $3.61, a decline of over 53% in one day [2] - Shareholders interested in serving as lead plaintiff must submit their papers by October 6, 2025, and do not need to participate in the case to be eligible for recovery [3] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Group 1 - A class action has been filed on behalf of investors who purchased Sable Offshore Corp. (NYSE: SOC) securities between May 19, 2025, and June 3, 2025, and/or traceable to the Company's May 21, 2025 secondary public offering [1] - The allegations state that Sable Offshore Corp. misled investors by claiming that oil production had restarted off the coast of California when it had not, leading to investor losses when the truth was revealed [2] - Shareholders interested in serving as lead plaintiff must submit their papers by September 26, 2025, and can remain absent class members if they choose not to participate [3] Group 2 - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses for representation [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action has been filed against Unicycive Therapeutics, Inc. for allegedly misleading investors regarding the readiness of its drug application and compliance with FDA manufacturing requirements [1][2]. Group 1: Allegations and Legal Action - Robbins LLP is investigating allegations that Unicycive Therapeutics misled investors about the prospects of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) [2]. - The complaint claims that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements [2]. - Shareholders are encouraged to participate in the class action and can contact Robbins LLP before the October 14, 2025 deadline to serve as lead plaintiff [4]. Group 2: Stock Performance and FDA Actions - On June 10, 2025, Unicycive announced that the FDA identified deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of over 40% [3]. - Following the FDA's issuance of a Complete Response Letter for the OLC NDA on June 30, 2025, Unicycive's stock fell nearly 30%, closing at $4.77 per share [3].

Group 1 - A class action has been filed on behalf of investors who purchased Altimmune, Inc. (NASDAQ: ALT) securities between August 10, 2023, and June 25, 2025 [1] - Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1] - The allegations state that Altimmune misled investors regarding the viability of its IMPACT Phase 2b MASH trial, which failed to achieve statistical significance due to a higher-than-expected placebo response [2] Group 2 - Following the announcement of the trial results on June 26, 2025, Altimmune's stock price dropped from $7.71 per share to $3.61 per share, a decline of over 53% in one day [2] - Shareholders interested in serving as lead plaintiff must submit their papers by October 6, 2025, and do not need to participate in the case to be eligible for recovery [3] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of shareholders of Linage, Inc. (NASDAQ: LINE) due to allegations of misleading information in the company's IPO registration statement [1][2]. Allegations - The registration statement filed on June 26, 2024, allegedly contained false or misleading information regarding the company's financial health and market conditions [2]. - Key issues include: - Sustained weakening in customer demand due to increased cold-storage supply and destocking of excessive inventory from the COVID-19 pandemic [2]. - Price increases implemented prior to the IPO that could not be maintained amid declining demand [2]. - Inability to counteract adverse trends through operational efficiencies or competitive advantages [2]. - Contrary to claims of stable revenue growth and high occupancy rates, the company has been experiencing stagnant or falling revenue, occupancy rates, and rent prices [2]. - Overall, the company's financial results and business prospects have been materially impaired [2]. Stock Performance - Since the IPO, Linage's stock price has dropped to around $40 per share, significantly below the IPO price at the time of the complaint [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by September 30, 2025, but participation is not required for recovery eligibility [4].

Core Viewpoint - Robbins LLP has filed a class action on behalf of investors who acquired Fiserv, Inc. common stock during a specified period, alleging that the company misled investors regarding the growth prospects of its Clover platform [1][2]. Allegations - Fiserv allegedly forced Payeezy merchants to migrate to its Clover platform due to cost issues and problems with Payeezy, which temporarily boosted Clover's revenue and GPV growth, concealing a slowdown in new merchant business [2]. - Following the forced conversions, many former Payeezy merchants switched to competing solutions due to Clover's high pricing and inadequate customer service, leading to a significant slowdown in Clover's GPV growth and unsustainable revenue growth [2]. - The positive statements made by Fiserv regarding Clover's growth strategies and business prospects during the class period were claimed to be materially false and misleading [2]. Impact on Stock - The truth regarding these issues was revealed through a series of disclosures, resulting in a decline in Fiserv, Inc.'s stock and harming investors [3]. Next Steps for Shareholders - Shareholders interested in serving as lead plaintiffs must file their motions by September 22, 2025, while those who choose not to participate can remain as absent class members [4]. Company Background - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002, operating on a contingency fee basis where shareholders pay no fees or expenses [5].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to allegations of misleading investors regarding its integration with 3M Company, which has negatively impacted its financial health [2][3]. Financial Performance - On January 10, 2025, Neogen reported a GAAP net income that was significantly negative, primarily due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition [3]. - Neogen cut its fiscal year 2025 revenue and EBITDA guidance following the negative financial disclosures [3]. - On April 9, 2025, Neogen announced a quarterly revenue decline of 3.4% to $221 million, attributing part of this to integration issues, and again revised its FY25 revenue and EBITDA outlook downward [4]. - The company projected capital expenditures of $100 million due to lowered adjusted EBITDA and a pull-forward of integration-related capital expenditures into FY25 [4]. - On June 4, 2025, Neogen expected its EBITDA margin to be in the high teens, a significant drop from the previous quarter's margin of 22% [5]. Stock Performance - Following the January 10, 2025 announcement, Neogen's stock price fell by 5% to close at $12.36 per share [3]. - After the April 9, 2025 announcement, the stock price plummeted by 28% [4]. - By June 4, 2025, the stock price had further declined by 17%, closing at $4.96 per share, marking a total drop of $18.88 per share or 79% from its August 15, 2023 high of $23.84 per share, erasing over $4 billion in market capitalization [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Flywire Corporation securities between February 28, 2024, and February 25, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint asserts that Flywire Corporation failed to disclose that the strength and sustainability of its revenue growth was overstated [2]. - It also claims that the negative impact of permit- and visa-related restrictions on Flywire's business was understated [2]. Financial Performance - On February 25, 2025, Flywire announced disappointing financial results for the fourth quarter and fiscal year 2024, revealing expectations of over a 30% year-over-year revenue decline in both Canadian and Australian markets due to recent policy changes and new visa rules [3]. - The company cited similar headwinds in the U.S. market related to shifting visa trends [3]. - Following these disclosures, Flywire's stock price fell by $6.59 per share, or 37.36%, closing at $11.05 per share on February 26, 2025 [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Flywire Corporation, with options to serve as lead plaintiff or remain an absent class member [4].

Group 1 - A class action has been filed on behalf of investors who purchased Sable Offshore Corp. (NYSE: SOC) securities between May 19, 2025, and June 3, 2025, related to the company's secondary public offering on May 21, 2025 [1][2] - The allegations state that Sable Offshore Corp. misled investors by claiming that oil production had restarted off the coast of California when it had not, leading to investor losses when the truth was revealed [2] - Shareholders interested in serving as lead plaintiff must submit their papers by September 26, 2025, and can choose to remain absent class members if they do not wish to participate [3] Group 2 - Robbins LLP is a recognized leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Lockheed Martin Corporation securities between January 23, 2024, and July 21, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Allegations - The complaint states that Lockheed Martin failed to disclose several critical issues, including: - Inefficient internal controls related to risk-adjusted contracts and profit booking rates [2] - Lack of effective procedures for comprehensive reviews of program requirements and risks [2] - Overstatement of its ability to meet contract commitments regarding cost, quality, and schedule [2] - Likelihood of reporting significant losses as a result of these issues [2] Financial Impact - On July 22, 2025, Lockheed Martin disclosed an additional $1.6 billion in pre-tax losses on classified programs, which included: - $950 million in losses from the Aeronautics Classified program - $570 million in losses from the Canadian Maritime Helicopter Program - $95 million charge related to the Turkish Utility Helicopter Program - Following this announcement, the company's share price dropped by $49.79, or over 10%, closing at $410.74 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers by September 26, 2025, but participation is not required to be eligible for recovery [4].